To (i) quantify the cost of multiple sclerosis (MS) to the Canadian health
care system and society; (ii) measure health utility in MS patients, and (i
ii) examine the influence of disability on patient utility and health core
costs. Materials and methods: A comprehensive patient survey and chart revi
ew of relapsing MS patients in remission, relapse and recalling a relapse.
Results: Annual remission costs increased with EDSS level ($7596 at EDSS 1,
$33 206 at EDSS 6). At all EDSS levels the largest costs were due to inabi
lity to work, which increased with EDSS. The average relapse cost for all E
DSS levels was $1367. An inverse correlation was found between EDSS level a
nd patient utility for patients in remission and relapse. The decrease in r
emission health utility from EDSS 1 to 6 was 0.24, which is 25% greeter tha
n the difference in health status between on average 25 and 85 year-old Con
clusions: This study demonstrates that MS Produces substantial health core
costs and reductions in patient quality of life end ability to work, losses
that con be avoided or delayed if disease Progression is slowed. These dat
a provide health-care decision-makers with the opportunity to consider the
full impact of MS when faced with budget allocation decisions.